Add like
Add dislike
Add to saved papers

The Plasticity of CD4 + CD25 + FOXP3 + CD127 low T Cells in Patients with Metastatic Renal Cell Carcinoma in the Course of Interferon-Alpha Immunotherapy.

Aims: To examine changes in subpopulation of CD4+ CD25+ Foxp3+ CD127low T lymphocytes (Treg) and their association with the efficiency of the IFN- α therapy.

Materials and Methods: Pts with mRCC who had undergone nephrectomy were treated with IFN- α at a dose of 6 × 106  U/day three times a week ( n = 18). An immunophenotypic analysis of lymphocytes in peripheral blood expressing CD4, CD25, CD127, and Foxp3 antigens could be performed in 18 pts before, 2 weeks, and 2 mo after IFN- α therapy and 22 normal volunteers. Blood samples were collected at baseline and 2 mo after treatment start. Serum levels of TGF- β 1, IL-17A, and Epo were measured by ELISA.

Results: PR was achieved in 3 (16.6%) pts who received first-line therapy. Long-lasting SD (≥6 months) was noted in 6 (33.3%) pts. The median progression free survival (PFS) was 4 mo (95% CI: 2-NE). The study of the population of Treg indicated that there were no significant differences in the groups depending on the effect ( p = 0.71). In one patient, the reduction of Treg cells was associated with increased TGF- β and IL-17 levels, whereas in other two pts the increase in Treg cells was associated with decreased TGF- β and IL-17 levels. The endogenous levels of Epo did not show significant correlation with response to IFN- α immunotherapy. In the patient subgroup with an initial value of MCH > 31 pg, the median PFS was not achieved, but in the subgroup with an initial value of MCH < 31 pg, the median PFS was 2 months ( p = 0.032).

Conclusions: In our study, we have described functional plasticity of Treg cells, which prevents them from being used as a prognostic marker. The conversion of Treg cells into Th17 can serve as a basis for the development of a new specific immunotherapeutic method in oncology after confirmation in the experiment in vitro. Given the small dataset, the results will need further validation.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app